bioAffinity Technologies (NASDAQ: BIAFW) soared over 52% in pre-market trading to $0.1164 after the company released three case studies demonstrating the clinical efficacy of its CyPath lung cancer diagnostic test. These studies showed how this non-invasive test helped one patient detect stage 1A lung cancer, spared another patient from unnecessary biopsies, and guided the treatment decisions of a high-risk chronic obstructive pulmonary disease (COPD) patient. The company's technology demonstrated 92% sensitivity and 87% specificity in clinical studies, meeting a critical need for early lung cancer detection. Meanwhile, the company will continue to advance its commercialization efforts, with revenues expected to reach $1.27 million in the second quarter of 2025.